Company Overview
| Stock Name | Mega Genomics |
|---|---|
| Stock Code | 06667 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 中國領先的基因檢測平台公司,專注於消費級基因檢測及癌症篩查服務,提供涵蓋營養與代謝、癌症風險評估、慢性疾病易感性、藥物遺傳學檢測及傳染病檢測的基因檢測服務,並提供結直腸癌及胃癌等非侵入性癌症篩查。 |
| Listing Date | 2022-06-22 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京海淀區花園北路健康智谷401 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | megagenomics.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 18.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 3,600 |
| Par Value | To be extracted |
| Offer Period | 2022-06-10 to 2022-06-15 |
| Global Offering Shares | 11,961,800 shares |
| HK Public Offer Shares (Initial) | 1,196,200 shares (10.0%) |
| Public Offer Lots (Initial) | 5,981lots (Pool A2,990lots,Pool B2,991lots) |
| International Placing Shares (Initial) | 10,765,600 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 239,233,800 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 81.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 215,312,400 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,600 |
| 2 lots | 400 | HK$ 7,200 |
| 3 lots | 600 | HK$ 10,800 |
| 4 lots | 800 | HK$ 14,400 |
| 5 lots | 1,000 | HK$ 18,000 |
| 6 lots | 1,200 | HK$ 21,600 |
| 7 lots | 1,400 | HK$ 25,200 |
| 8 lots | 1,600 | HK$ 28,800 |
| 9 lots | 1,800 | HK$ 32,400 |
| 10 lots | 2,000 | HK$ 36,000 |
| 15 lots | 3,000 | HK$ 54,000 |
| 20 lots | 4,000 | HK$ 72,000 |
| 25 lots | 5,000 | HK$ 90,000 |
| 30 lots | 6,000 | HK$ 108,000 |
| 35 lots | 7,000 | HK$ 126,000 |
| 40 lots | 8,000 | HK$ 144,000 |
| 45 lots | 9,000 | HK$ 162,000 |
| 50 lots | 10,000 | HK$ 180,000 |
| 100 lots | 20,000 | HK$ 360,000 |
| 150 lots | 30,000 | HK$ 540,000 |
| 200 lots | 40,000 | HK$ 720,000 |
| 250 lots | 50,000 | HK$ 900,000 |
| 300 lots | 60,000 | HK$ 1,080,000 |
| 350 lots | 70,000 | HK$ 1,260,000 |
| 450 lots | 90,000 | HK$ 1,620,000 |
| 500 lots | 100,000 | HK$ 1,800,000 |
| 1,000 lots | 200,000 | HK$ 3,600,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,500 lots | 300,000 | HK$ 5,400,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.52B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +519% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 4,306,208,400 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣79.0百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue | 123,700 | 203,220 | 237,185 |
| Cost of sales | -45,224 | -56,979 | -70,509 |
| Gross profit | 78,476 | 146,241 | 166,676 |
| Other income and gains, net | 14,524 | 3,680 | 14,265 |
| Selling and distribution expenses | -4,944 | -19,475 | -22,977 |
| Administrative expenses | -15,583 | -18,553 | -22,968 |
| Net finance costs | -3,052 | -1,851 | -785 |
| Profit before tax | 38,292 | 94,903 | 95,882 |
| Income tax expense | -8,601 | -15,806 | -16,867 |
| Profit for the year | 29,691 | 79,097 | 79,015 |
| Profit attributable to owners | 29,691 | 79,097 | 79,015 |
Balance Sheet
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Cash and cash equivalents | 52,646 | 208,450 | 239,096 |
| Trade and bills receivables | 108,125 | 130,234 | 203,630 |
| Inventories | 2,440 | 2,972 | 3,284 |
| Total current assets | 184,380 | 358,108 | 685,362 |
| Total assets | 263,745 | 453,573 | 772,183 |
| Total current liabilities | 53,069 | 262,365 | 69,791 |
| Total liabilities | 266,447 | 277,178 | 77,687 |
| Total equity | -2,702 | 176,395 | 694,496 |
| Equity attributable to owners | -2,702 | 176,395 | 694,496 |
| Interest-bearing borrowings | 13,060 | 2,654 | 0 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Net cash from operating activities | 37,272 | 102,836 | 30,629 |
| Net cash from investing activities | 17,668 | -31,087 | -1,714 |
| Net cash from financing activities | -20,279 | 84,055 | 2,620 |
| Net increase in cash | 34,661 | 155,804 | 31,535 |
| Depreciation of PP&E | 8,573 | 8,532 | 8,355 |
| Depreciation of right-of-use assets | 5,412 | 5,411 | 5,412 |
| Amortisation of intangible assets | 69 | 93 | 106 |
| Purchase of PP&E | -581 | -1,045 | -4,159 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 18.0 |
|---|---|
| First Day Open | HK$ 19.48 |
| First Day Change | -61.39% |
| First Day Volume | 3858800.0 |
| First Day Turnover | 74244600.0 |
| Use of Proceeds | 1、約30%或46.0百萬港元將用于我們的消費級基因檢測及癌癥篩查服務及產品的銷售、營銷及商業化;
2、約25%或38.4百萬港元將投資于研發我們的服務及產品;
3、約20%或30.7百萬港元將用于增加或擴大我們的檢測能力及產能;
4、約15%或23.0百萬港元將用于通過投資或收購具吸引力的技術或檢測相關公司,為我們在整個行業價值鏈的擴張提供資金;
5、約10%或15.3百萬港元預期將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中信建投(国际)融资有限公司 CE BAU112
Overall Coordinators (3)
Joint Bookrunners (7)
Joint Lead Managers (7)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 迈克生物股份有限公司 | 58,158,000 HKD | — | 27.01% | — | 6 months | 2022-12-22 |
| 2 | 南昌工控园区股权投资合伙企业(有限合伙) | 81,414,000 HKD | — | 37.81% | — | 6 months | 2022-12-22 |
| 3 | 南昌金融控股有限公司 | 34,898,400 HKD | — | 16.21% | — | 6 months | 2022-12-22 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 林琳 | — |
| Company Secretary | 李艷、伍偉琴 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Mei Nian Investment Limited(美年大健康)15.57%;俞博士18.73%;受限制股份單位代名人(嘉士圖有限公司)11.40%;郭女士9.20%;天津世紀宇能企業管理合夥企業(有限合夥)5.06% |
|---|




